Objective: It is urgent to search for additional opportunities in the prevention and treatment of diabetic peripheral neuropathy (DPN). Aim. To assess the effect of vitamin D and Benfotiamine on the clinical manifestations of DPN in patients with type 2 diabetes mellitus (T2DM). Materials and methods. 68 patients with type 2 diabetic patients with diabetic peripheral neuropathy were randomized to either to receive Benfotiamine (200mg/day), (group 1, n=35) and 40000IU (group 2, n=33,) weekly for 18 weeks. At the beginning and at the end of the study determined the levels of 25(OH)D, HbA1c, conducted a survey on the scales of NSS, NDS, NTSS-9 and VAS. The difference (Δ) in/between the groups according to the studied parameters was estimated. Results. Initially, the groups were comparable in levels 25(OH)D, HbA1c and the NDS, NSS, VAS and NTSS-9 scales (for all p>0.05). In the final significant reduction of symptoms of DPN occurred only in group 2: NDS Δ=-21.82%, NSS Δ=-18.44%, VAS Δ=-12.05%, NTSS-9 (all p0.05). Significant correlations were identified in group 2 between levels of 25(OH)D and: NDS (p=0.030); VAS (r=0.338, p=0.045); with HbA1c (p=0.031); BMI (p=0.035). Conclusions. Taking vitamin D at a dose of 40 000 IU/week of colecalciferol for 18 weeks reduced the severity of neurological symptoms (NDS, NSS, VAS, NTSS-9) in patients with T2DM and DPN and contributed to the improvement of metabolic metabolism (reduction of HbA1c and BMI). Conclusion: The addition of 40,000 IU/ week of colecalciferol to patients with T2DM and DPN may affect the severity of DPN.